

Matthias Pinter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5870099/publications.pdf>

Version: 2024-02-01

96
papers

5,565
citations

117625

34
h-index

88630

70
g-index

96
all docs

96
docs citations

96
times ranked

6551
citing authors

#	ARTICLE	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
2	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. <i>Cancer Discovery</i> , 2016, 6, 852-869.	9.4	318
3	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	7.3	288
4	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	12.1	275
5	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	232
6	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	7.1	213
7	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016, 1, e000042.	4.5	194
8	Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. <i>Radiology</i> , 2012, 263, 590-599.	7.3	177
9	Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis. <i>Oncologist</i> , 2009, 14, 70-76.	3.7	169
10	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 6220.	3.3	155
11	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	153
12	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021, 70, 204-214.	12.1	150
13	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	3.7	139
14	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
15	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 598-609.	3.7	131
16	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
17	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	7.3	112
18	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	3.7	106

#	ARTICLE	IF	CITATIONS
19	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	3.7	105
20	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2224-2234.	7.3	101
21	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	3.7	96
22	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 395-402.	1.9	93
23	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5959-5969.	7.0	75
24	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	7.3	60
25	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
26	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
27	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
28	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	3.8	49
29	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 714-726.	3.9	49
30	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 203-217.	7.7	48
31	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	3.7	47
32	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
33	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
34	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	3.2	43
35	Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events. <i>Clinical Cancer Research</i> , 2018, 24, 3803-3812.	7.0	40
36	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39

#	ARTICLE	IF	CITATIONS
37	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	3.9	36
38	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
39	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23684-23694.	7.1	32
40	Novel reliability criteria for controlled attenuation parameter assessments for noninvasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	3.8	30
41	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. <i>EMBO Reports</i> , 2020, 21, e50893.	4.5	29
42	Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2 ^{loxP/loxP} /Villin-Cre mice. <i>Gut</i> , 2015, 64, 1905-1912.	12.1	26
43	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
44	Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. <i>Cancers</i> , 2022, 14, 1722.	3.7	26
45	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
46	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
47	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 10054-10068.	1.8	25
48	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0181878.	2.5	24
49	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.9	23
50	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , 2019, 14, e0216677.	2.5	22
51	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	3.8	22
52	Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 1012-1019.	1.6	20
53	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1732-1741.	6.4	20
54	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	3.9	20

#	ARTICLE	IF	CITATIONS
55	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
56	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	3.8	18
57	Sequential systemic treatment in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 205-212.	3.7	17
58	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	4.3	16
59	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	2.5	16
60	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	3.9	16
61	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.9	15
62	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
63	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	3.9	14
64	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
65	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	5.1	11
66	Epidemiological Trends of Hepatocellular Carcinoma in Austria. <i>Digestive Diseases</i> , 2014, 32, 664-669.	1.9	10
67	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	2.8	9
68	Synthesis and Cytotoxic Activity of Chiral Sulfonamides Based on the 2-Azabicycloalkane Skeleton. <i>Molecules</i> , 2020, 25, 2355.	3.8	9
69	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	2.3	8
70	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	3.7	8
71	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Hepatology Communications</i> , 2021, 5, 1939-1952.	4.3	8
72	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	3.7	7

#	ARTICLE	IF	CITATIONS
73	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. Memo - Magazine of European Medical Oncology, 2018, 11, 185-192.	0.5	6
74	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Digestive and Liver Disease, 2020, 52, 1473-1479.	0.9	6
75	Cytotoxic Activity of Piperazin-2-One-Based Structures: Cyclic Imines, Lactams, Aminophosphonates, and Their Derivatives. Materials, 2021, 14, 2138.	2.9	6
76	A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. International Journal of Oncology, 2021, 59, .	3.3	6
77	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Oncotarget, 2017, 8, 57109-57120.	1.8	5
78	Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort" more questions than answers. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 231-232.	3.7	5
79	Alpha-fetoprotein-adjusted alpha-HCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterology Journal, 2021, 9, 209-219.	3.8	5
80	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. Journal of Personalized Medicine, 2021, 11, 281.	2.5	5
81	Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.. Journal of Clinical Oncology, 2020, 38, e16668-e16668.	1.6	5
82	Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018. Cancers, 2022, 14, 3093.	3.7	5
83	Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab. Memo - Magazine of European Medical Oncology, 0, , 1.	0.5	2
84	Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection. Journal of Hepatology, 2022, , .	3.7	2
85	Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease, 2022, 54, 1222-1229.	0.9	2
86	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2022, 40, 399-399.	1.6	1
87	Reply to: "The CRAFTY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy". Journal of Hepatology, 2022, 76, 1233-1234.	3.7	1
88	Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma" authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 341-342.	3.7	0
89	Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma". Liver Cancer, 2020, 9, 107-107.	7.7	0
90	Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?". Liver Cancer, 2020, 9, 110-111.	7.7	0

#	ARTICLE	IF	CITATIONS
91	Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 917-918.	3.7	0
92	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
93	A patient with liver cirrhosis and hepatic lesions. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 309-312.	0.5	0
94	Comparative outcome of sorafenib treatment in central Europe and Russia.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14681-e14681.	1.6	0
95	Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?" <i>Journal of Hepatology</i> , 2022, 76, 988-989.	3.7	0
96	Reply to: "The CRAFTY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations" <i>Journal of Hepatology</i> , 2022, , .	3.7	0